Zobrazeno 1 - 10
of 13
pro vyhledávání: ''
Autor:
Sofia Sales Martins, Cláudia Porto, Marina Freitas Ferreira, Jorgeth de Oliveira Carneiro da Motta, Carmen Déa Ribeiro de Paula, Ciro Martins Gomes, Bruna Côrtes Rodrigues, Raimunda Nonata Ribeiro Sampaio, Daniel Holanda Barroso
Publikováno v:
International Journal for Parasitology: Drugs and Drug Resistance, Vol 14, Iss, Pp 257-263 (2020)
International Journal for Parasitology: Drugs and Drug Resistance
International Journal for Parasitology: Drugs and Drug Resistance
Introduction The standard therapy for American cutaneous leishmaniasis (ACL) is intravenous meglumine antimoniate (IV-MA). However, treatment interruptions due to adverse events (AEs) and non-adherence are frequent. Consequently, intralesional MA (IL
Publikováno v:
International Journal for Parasitology: Drugs and Drug Resistance, Vol 10, Iss, Pp 45-50 (2019)
International Journal for Parasitology: Drugs and Drug Resistance
International Journal for Parasitology: Drugs and Drug Resistance
The macrocyclic lactone anthelmintics are the only class of drug currently used to prevent heartworm disease. Their extremely high potency in vivo is not mirrored by their activity against Dirofilaria immitis larvae in vitro, leading to suggestions t
Autor:
Mohamed Abdo Rizk, Dickson Stuart Tayebwa, Azirwan Guswanto, Naoaki Yokoyama, Bumduuren Tuvshintulga, Ikuo Igarashi, Sambuu Gantuya, Amany Magdy Beshbishy, Gaber El-Saber Batiha, T Sivakumar, Arifin Budiman Nugraha
Publikováno v:
International Journal for Parasitology: Drugs and Drug Resistance, Vol 10, Iss, Pp 84-90 (2019)
International Journal for Parasitology: Drugs and Drug Resistance
International Journal for Parasitology: Drugs and Drug Resistance
Diminazene aceturate (DA) and imidocarb dipropionate are commonly used in livestock as antipiroplasm agents. However, toxic side effects are common in animals treated with these two drugs. Therefore, evaluations of novel therapeutic agents with high
Publikováno v:
International Journal for Parasitology: Drugs and Drug Resistance
International Journal for Parasitology: Drugs and Drug Resistance, Vol 11, Iss, Pp 148-155 (2019)
International journal for parasitology. Drugs and drug resistance
International journal for parasitology. Drugs and drug resistance, Elsevier, 2019, 11, pp.148-155. ⟨10.1016/j.ijpddr.2019.06.001⟩
International Journal for Parasitology: Drugs and Drug Resistance, Vol 11, Iss, Pp 148-155 (2019)
International journal for parasitology. Drugs and drug resistance
International journal for parasitology. Drugs and drug resistance, Elsevier, 2019, 11, pp.148-155. ⟨10.1016/j.ijpddr.2019.06.001⟩
The development of an effective amphotericin B (AmB) topical formulation to replace the systemically toxic injections currently used in cutaneous leishmaniasis (CL) treatment is challenging due to poor absorption through the skin. Aiming at an effect
Autor:
Mark A. Burlingame, David Lee Nelson, R. Jeffrey Neitz, Alan R. Wolfe, Brian M. Suzuki, K. C. Lim, Leslie Z. Benet, Mark A. Scheideler, Conor R. Caffrey
Publikováno v:
International Journal for Parasitology: Drugs and Drug Resistance, Vol 8, Iss 3, Pp 571-586 (2018)
International journal for parasitology. Drugs and drug resistance, vol 8, iss 3
International Journal for Parasitology: Drugs and Drug Resistance
International journal for parasitology. Drugs and drug resistance, vol 8, iss 3
International Journal for Parasitology: Drugs and Drug Resistance
Treatment of schistosomiasis relies precariously on just one drug, praziquantel (PZQ). In the search for alternatives, 15 S-[2-(alkylamino)alkane] thiosulfuric acids were obtained from a previous research program and profiled in mice for efficacy aga
Autor:
Lombardi, F, Giacomelli, A, Armenia, D, Lai, A, Dusina, A, Bezenchek, A, Timelli, L, Saladini, F, Vichi, F, Corsi, P, Colao, G, Bruzzone, B, Gagliardini, R, Callegaro, A, Castagna, A, Santoro, Mm, ARCA Study, Group.
Despite successful antiretroviral therapy (ART), patients infected with human immunodeficiency virus (HIV) can develop multi-class drug resistance (MDR). This retrospective study aimed to explore the prevalence of HIV-1 drug resistance over the past
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::303752fc95f72b0ec269042b0857929e
http://hdl.handle.net/10807/214185
http://hdl.handle.net/10807/214185
The file attached to this record is the author's final peer reviewed version. The Publisher's final version can be found by following the DOI link Abnormalities in the cerebellar circuitry have been suggested to contribute to some of the symptoms ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb656827a3f0baeb5b75bc491cf8fe98
https://doi.org/10.1016/j.euroneuro.2018.02.002
https://doi.org/10.1016/j.euroneuro.2018.02.002
Background Adenosine 5’-triphosphate (ATP) stimulates pulmonary vagal slow conducting C-fibres and fast conducting Aδ-fibres with rapidly adapting receptors (RARs). Pulmonary C-fibres but not RARs are also sensitive to capsaicin, a potent tussigen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8463d1d3a13574c608054ac9c3151416
http://hdl.handle.net/10044/1/52034
http://hdl.handle.net/10044/1/52034
Autor:
Mercè Torra, A. Callari, Eduard Vieta, Jose Manuel Goikolea, Víctor Pérez-Sola, F. Colom, Andrea Murru, Isabella Pacchiarotti, C. Varo, Soledad Romero, B. Gonzalez de la Presa
Lithium (Li) and valproate (VPA) are used in the treatment of bipolar disorder (BD), with narrow therapeutic window requiring periodic control of serum levels. This prevents intoxication, lack of efficacy due to low serum concentrations, and allows m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ce2d9e34b46acb71c8b2b5985e332ad
http://hdl.handle.net/10230/34705
http://hdl.handle.net/10230/34705
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
Brexpiprazole (BREX), a recently approved antipsychotic drug in the US and Canada, improves cognitive dysfunction in animal models, by still largely unknown mechanisms. BREX is a partial agonist at 5‐HT1A and D2 receptors and antagonist at α1B- an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4062ab0370c7fecf7cf5c862ef5b8e3f
http://hdl.handle.net/10261/159391
http://hdl.handle.net/10261/159391